Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheldon Tobe

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
International Journal of Nephrology and Renovascular Disease|April 10, 2019
Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) studyTian Chen, Pamela Brewster, Katherine R Tuttle, et al.
Diabetes, Obesity & Metabolism|February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathyHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism|April 1, 2018
Baseline characteristics and enrichment results from the SONAR trialHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A <i>Post Hoc</i> Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.
European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.
JACC. Heart Failure|June 30, 2022
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart FailureJ David Smeijer, Jeroen Koomen, Donald E Kohan, et al.
Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 31, 2018
Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trialAmit X Garg, P J Devereaux, Andrew Hill, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
Journal of the American Society of Hypertension : JASH|June 9, 2015
Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosisDavid A Folt, Kaleigh L Evans, Sravya Brahmandam, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
International Journal of Nephrology and Renovascular Disease|April 10, 2019
Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) studyTian Chen, Pamela Brewster, Katherine R Tuttle, et al.
Diabetes, Obesity & Metabolism|February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathyHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism|April 1, 2018
Baseline characteristics and enrichment results from the SONAR trialHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A <i>Post Hoc</i> Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.
European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.
JACC. Heart Failure|June 30, 2022
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart FailureJ David Smeijer, Jeroen Koomen, Donald E Kohan, et al.
Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 31, 2018
Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trialAmit X Garg, P J Devereaux, Andrew Hill, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
Journal of the American Society of Hypertension : JASH|June 9, 2015
Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosisDavid A Folt, Kaleigh L Evans, Sravya Brahmandam, et al.
Pageof 7